

Czech Republic

Research and innovation situation in the industrial biotechnology

Budgetary aspects

SWOT

S Strong horizontal funding system (27 → 10 granting agencies) Improved (improving?) budget	W Atomization No specific focused program for industrial biotechnology Lack of continuity in the administration Lack of strategy
O Focusing Quality improvement EU funds - money & better evaluation of the projects	T Lack of human resources (both quantity and quality) Administration system (incompetent officials) Decreased budget a/o stagnation CZK exchange rate

Development of the biotechnological sector

SWOT

S Strong traditional biotechnology Strong biotechnology in pharma generics prods. Engineering and machinery for biotechnology Good level of research and education	W Lack of white biotechnology Lack of biotech. SME, lack of venture capital Lacks in technology transfers from R&D to industry
O Implementation of the „green” processes Biofuels Algae; waste treatment Food crisis Implementation of REACH (pressure to alternative bio materials/processes)	T Food crisis

Recommendations

CZ

EU

Improve quality of evaluation and follow up of the „matching funds“ programs	Fund also (more!) basic research
Train grant managers; invest more money in the evaluation and peer review procedures	Reduce bureaucracy
To foster excellence in the basic research	Make FP7 web more intelligible
Incentives for patenting	More flexibility in programs
Incentives for private spending in biotech	Feedback in the reviewing procedures (NIH style)
Improve public awareness of bio products (good practice examples, PR)	
Public procurement	
Improve awareness of the company managers of the bioprocesses available	